Advertisement

Topics

Shire CEO: Mydayis To Be Big ADHD Drug, But No Ex-US Launch Planned (Yet)

14:44 EDT 21 Jun 2017 | SCRIP

Flemming Ornskov says FDA approval of long-lasting ADHD therapy Mydayis is part of Shire's plan to dramatically increase neuroscience revenues...

      

Related Stories

 

Original Article: Shire CEO: Mydayis To Be Big ADHD Drug, But No Ex-US Launch Planned (Yet)

NEXT ARTICLE

More From BioPortfolio on "Shire CEO: Mydayis To Be Big ADHD Drug, But No Ex-US Launch Planned (Yet)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Psychiatry
Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...